Offering new drug-candidates the best chances of success, by assessing their effects on mitochondria, is our driver since 2009.
Mitologics is thus thrilled to join BIO-Europe this autumn to put this important topic on the table one more time.
With 320+ projects in the field of mitochondrial toxicity and efficacy for pharma, biotech, and cosmetic industries under our belt, we look forward to meeting companies facing questions or issues in this field.
Feel free to schedule a meeting with our CEO, Dr Annie Borgne-Sanchez, to share your story and see how our services, designed to track and analyse if and how compounds affect or protect mitochondrial functionality and integrity, meet your needs.
Learn more about Mitologics’ toxicity services, efficacy services, or our proprietary technologies.
